WINDTREE THERAPEUTICS INC /DE/ (WINT) - Dilution Analysis

10-Q filing | 33.6M shares outstanding

S-1 filing: This S-1 filing discusses the beneficial ownership of shares, a material relationship between selling stockholders and the company, and various corporate actions including a crypto treasury strategy, an increase in authorized shares, and an amendment to an ELOC Purchase Agreement.

10-Q filing | 9.2M shares outstanding

8-K filing: Windtree Therapeutics, Inc. entered into a securities purchase agreement to sell and issue approximately 60,000 shares of Series E Convertible Preferred Stock at $1,000 per share and warrants to purchase up to 66,000,000 shares of common stock, with a potential increase to 200,000 preferred shares, for an aggregate offering price of up to $200 million, intending to use the proceeds to acquire BNB as a treasury strategy. ($60.0M proceeds)

S-1/A filing: This S-1/A filing relates to the offer and resale of up to 62,600,618 shares of common stock by selling stockholders, including shares issuable upon conversion of Series D convertible preferred stock, Senior Secured Promissory Notes, and warrants.

S-1/A filing: This S-1/A filing relates to the offer and resale by selling stockholders of up to 42,168,035 shares of common stock issuable upon conversion of Series D convertible preferred stock.

S-1 filing: This S-1 filing relates to the offer and resale by selling stockholders of up to 42,168,035 shares of common stock issuable upon conversion of Series D convertible preferred stock.

10-Q filing | 3.6M shares outstanding

8-K filing: Windtree Therapeutics, Inc. completed a private placement of 3,125 shares of Series D Convertible Preferred Stock for gross proceeds of approximately $2.5 million on April 30, 2025. ($2.5M proceeds)

8-K filing: Windtree Therapeutics, Inc. entered into a Securities Purchase Agreement for a private placement of 3,125 shares of Series D Convertible Preferred Stock for approximately $2.5 million in gross proceeds, expected to close on April 30, 2025. ($2.5M proceeds)

S-1/A filing: This prospectus relates to the offer and resale of common stock issuable upon the conversion of Series C convertible preferred stock, the exercise of certain warrants, the conversion of promissory notes, and pursuant to an equity line of credit.

S-1/A filing: This S-1/A filing registers the resale of common stock by selling stockholders, including shares issuable upon conversion of Series C preferred stock and promissory notes, exercise of warrants, and shares under an equity line of credit agreement.

10-K filing | 0.3M shares outstanding

8-K filing: Stock split 1-for-50 | Outstanding: 37,467,075 → 749,341

S-1 filing: This S-1 filing registers up to 40,000,000 shares of common stock issuable pursuant to an ELOC Purchase Agreement with Seven Knots, LLC, representing up to $23.8 million in aggregate gross proceeds for the company.

10-Q filing | 2.3M shares outstanding

8-K filing: Windtree Therapeutics, Inc. filed a prospectus supplement relating to the issuance and sale of up to $27,243,504 of shares of its common stock to Seven Knots, LLC under an existing equity line of credit, and as of October 25, 2024, the Company issued 5,499,273 shares of Common Stock for total gross cash proceeds of $7,756,496 pursuant to the Purchase Agreement. ($7.76M proceeds)

8-K filing: Windtree Therapeutics, Inc. sold 790,500 shares of Common Stock for gross proceeds of $1.7 million, converted 2,368 Preferred Shares into 1,278,452 shares of Common Stock, and redeemed 611 Preferred Shares for $0.8 million. ($1.7M proceeds)

8-K filing: The Company sold 949,948 shares of Common Stock for $3.2 million and converted 202.5 Preferred Shares into 68,877 shares of Common Stock, increasing the Common Stock outstanding from 591,909 shares as of June 30, 2024 to 1,610,734 shares as of September 13, 2024. ($3.2M proceeds)

S-1 filing: This prospectus relates to the potential resale from time to time by Seven Knots, LLC, or Seven Knots or the Selling Stockholder, of up to 10,679,758 shares of common stock.

S-3 filing: This prospectus relates to the offer and resale of common stock issuable upon conversion of Series C preferred stock and exercise of warrants.

10-Q filing | 0.6M shares outstanding

8-K filing: Windtree Therapeutics, Inc. entered into a Securities Purchase Agreement for a private placement of Series C Convertible Preferred Stock and warrants to acquire common stock for gross proceeds of approximately $1.0 million, intending to use the proceeds for working capital and general corporate purposes. ($1.0M proceeds)

8-K filing: Windtree Therapeutics, Inc. entered into a Securities Purchase Agreement for a private placement involving Series C Convertible Preferred Stock and warrants, with gross proceeds of approximately $12.9 million, and filed a Certificate of Designations for the Series C Preferred Stock. ($12.9M proceeds)

10-Q filing | 0.5M shares outstanding

8-K filing: Stock split 1-for-18 | Outstanding: 5,996,586 → 333,143

S-3/A filing: This is an S-3/A filing for a shelf offering of common stock by selling stockholders, including Deerfield PDI Financing II, L.P., with sales potentially occurring at prevailing market prices.

10-K filing | 6.0M shares outstanding

8-K filing: Windtree Therapeutics issued 5,500 shares of Series B Convertible Preferred Stock to certain creditors of Varian Biopharmaceuticals as part of an asset purchase agreement, with each share initially convertible into 15,265 shares of Common Stock. ($5.5M proceeds)

S-3 filing: This is an S-3 filing for a shelf offering of common stock by selling stockholders.

8-K filing: Windtree Therapeutics, Inc. issued 608,272 shares of common stock to Deerfield Management Company in exchange for termination of milestone payment rights, with the company also paying $200,000 in cash.

10-Q filing | 5.1M shares outstanding

10-Q filing | 5.1M shares outstanding

10-Q filing | 0.9M shares outstanding

8-K filing: Windtree Therapeutics, Inc. closed a public offering of 3,686,006 shares of common stock and accompanying warrants, with an additional 552,900 shares and warrants sold through the underwriter's option, at a price of $2.93 per share and warrant, resulting in net proceeds of approximately $10.8 million. ($0.0M proceeds)

S-1/A filing: The company is offering 2,008,928 shares of common stock and warrants to purchase up to 2,008,928 shares of common stock, as well as pre-funded warrants to purchase up to 2,008,928 shares of common stock with accompanying warrants.

S-1/A filing: The company is offering 2,008,928 shares of common stock and warrants to purchase up to 2,008,928 shares of common stock, as well as pre-funded warrants to purchase up to 2,008,928 shares of common stock.

S-1/A filing: This is an S-1/A filing for offering 1,948,051 shares of common stock and warrants to purchase up to 1,948,051 shares of common stock, as well as pre-funded warrants to purchase up to 1,948,051 shares of common stock and accompanying common warrants.

10-K filing | 0.8M shares outstanding

8-K filing: Stock split 1-for-50 | Outstanding: 31,135,000 → 622,700

8-K filing: Windtree Therapeutics, Inc. entered into a warrant exercise inducement offer letter with a holder to amend existing warrants, lowering the exercise price to $0.1411 per share, and the holder agreed to exercise warrants to purchase 1,112,308 shares of common stock for approximately $157,000, in exchange for new warrants to purchase up to 2,224,616 shares of common stock. ($0.16M proceeds)

S-1 filing: The company is offering common stock, pre-funded warrants to purchase common stock, and common warrants to purchase common stock.

8-K filing: Windtree Therapeutics entered into warrant exercise inducement offer letters with certain holders to amend and exercise existing warrants to purchase an aggregate of 4,808,595 shares of common stock at a reduced exercise price of $0.20 per share, in exchange for new warrants to purchase up to 9,617,190 shares of common stock, with the company expecting gross proceeds of approximately $1.0 million. ($1.0M proceeds)

10-Q filing | 31.1M shares outstanding

10-Q filing | 29.2M shares outstanding

10-Q filing | 28.3M shares outstanding

10-K filing | 28.3M shares outstanding

S-3 filing: The company may offer and sell up to $100,000,000 in the aggregate of common stock, preferred stock, debt securities, subscription rights, and 170,000 shares of common stock issuable upon the exercise of warrants from time to time in one or more offerings.

10-Q filing | 26.7M shares outstanding

10-Q filing | 26.7M shares outstanding

10-Q filing | 26.3M shares outstanding

10-K filing | 26.3M shares outstanding

8-K filing: Windtree Therapeutics, Inc. entered into an underwriting agreement with Oppenheimer & Co. Inc. for a public offering of 9,230,500 shares of its common stock and warrants to purchase 9,230,500 shares of its common stock at a combined price of $3.25 per share and warrant. ($29.97M proceeds)

10-Q filing | 16.9M shares outstanding

S-3 filing: The company is filing an S-3 to offer and sell up to $75,000,000 in the aggregate of common stock, preferred stock, and debt securities from time to time in one or more offerings.

10-Q filing | 16.9M shares outstanding

8-K filing: The company completed a public offering of 2,758,620 units, each consisting of one share of common stock and a warrant, with an additional 413,793 shares and/or warrants sold through the full exercise of the Overallotment Option. The offering price was $7.25 per unit, resulting in net proceeds of approximately $20.2 million after deducting underwriting discounts and commissions and estimated offering expenses.

S-1/A filing: This S-1/A filing outlines an offering of 2,094,240 units, each consisting of one share of common stock and a warrant to purchase one share of common stock, with an assumed public offering price of $9.55 per unit. The company intends to use the net proceeds from this offering primarily to advance (i) the study of KL4 surfactant to treat COVID-19 related lung injury; (ii) istaroxime phase 2 start-up activities; (iii) development of AEROSURF® for respiratory distress syndrome; (iv) pre-clinical studies of our oral SERCA2a activators to facilitate business development opportunities; and (v) for working capital, and/or general corporate purposes.

S-1/A filing: This S-1/A filing describes an offering of 523,560 units, each consisting of one share of common stock and a warrant to purchase 0.50 of a share of common stock, with an assumed public offering price of $9.55 per unit.

10-Q filing | 13.7M shares outstanding

S-1/A filing: This S-1/A filing describes an offering of units, each consisting of one share of common stock and a warrant to purchase 0.50 of a share of common stock, with an assumed offering price of $9.79 per unit and also includes an offering of warrants.

10-K filing | 41.1M shares outstanding

S-1 filing: This is an S-1 filing for Windtree Therapeutics, a clinical-stage biopharmaceutical and medical device company, including information on private placements, ATM programs, and a 401(k) plan employer match involving common stock and warrants.

S-1 filing: This is an S-1 filing for Windtree Therapeutics, a clinical-stage biopharmaceutical and medical device company, and includes information on private placement offerings, warrant issuances, and an at-the-market program.